Company intelligence / Profile preview

LIVIN

Chennai, Tamil Nadu, Indialivin.co.uk ↗

Ownership: Private
Employees: ~40
Development stage: Other

Overview

Levim Biotech successfully developed and launched a cost-effective liraglutide biosimilar—the first such launch in India—after completing Phase 1 and Phase 3 trials. The company has published clinical data in peer-reviewed journals and developed indigenous manufacturing capabilities for both the active ingredient and pen injection device. Other pipeline details are not specified.

Therapeutic areas: OncologyMetabolic DisordersInfectious Diseases
Modalities: Recombinant proteinPeptidesAntibody fragmentGene therapy products (recombinant technology)Polymer encapsulation (drug delivery)Nano-formulations
Industry: Biotech

Partnerships

Navitas Life Sciences (clinical research/CRO partner)

Beyond the preview

Go deeper on LIVIN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIVIN.

Explore the full profile